Literature DB >> 2857131

Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line.

M T Hierowski, C Liebow, K du Sapin, A V Schally.   

Abstract

A membrane receptor and a cytosolic receptor for somatostatin were found in a human undifferentiated pancreatic cancer cell line (MIA PaCa-2). Binding of somatostatin to this membrane receptor activates dephosphorylation of a phosphotyrosyl-membrane protein whose phosphorylation was promoted by epidermal growth factor (EGF). Vanadate, a purported inhibitor of dephosphorylation, interferes with the action of somatostatin. These findings suggest a possible biochemical mechanism by which somatostatin may inhibit the growth of human pancreatic cancers.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2857131     DOI： 10.1016/0014-5793(85)80529-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  27 in total

1.  Somatostatin inhibition of Ca2(+)-induced insulin secretion in permeabilized HIT-T15 cells.

Authors:  S Ullrich; M Prentki; C B Wollheim
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

Review 2.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.

Authors:  A Manni; A E Boucher; L M Demers; H A Harvey; A Lipton; M A Simmonds; M Bartholomew
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

5.  Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines.

Authors:  G Scambia; P B Panici; G Baiocchi; L Perrone; S Iacobelli; S Mancuso
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.

Authors:  C Liebow; M T Lee; A R Kamer; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 7.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

8.  Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence.

Authors:  C Liebow; D H Crean; A V Schally; T S Mang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Alterations in receptor-mediated kinases and phosphatases during carcinogenesis.

Authors:  D H Crean; C Liebow; M T Lee; A R Kamer; A V Schally; T S Mang
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Phosphorylation-regulated low-conductance Cl- channels in a human pancreatic duct cell line.

Authors:  F Becq; E Hollande; M Gola
Journal:  Pflugers Arch       Date:  1993-10       Impact factor: 3.657
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.